Tioma Therapeutics, Inc., a biopharmaceutical company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers, raised $86m in Series A financing.
The round was co-led by RiverVest Venture Partners (including 3×5 RiverVest Fund), Novo Ventures, Roche Venture Fund and S.R. One, Limited (the corporate venture capital arm of GlaxoSmithKline). In conjunction with the funding, John McKearn, PhD, of RiverVest Venture Partners, Peter Moldt, PhD, of Novo Ventures, Carole Nuechterlein of Roche Venture Fund and Jill Carroll of S.R. One will join Tioma’s board of directors, with Dr. McKearn serving as Chairman.
The company intends to use the proceeds to further develop its antibody portfolio, including its lead drug candidate, an anti-CD47 immune checkpoint inhibitor, through advanced proof-of-concept in human clinical trials.
Founded as Vasculox by scientific founders including William A. Frazier, PhD, professor of Biochemistry, Molecular Biophysics, Cell Biology, and Biomedical Engineering at Washington University School of Medicine and led by newly named President and Chief Executive Officer John Donovan, Tioma has generated a portfolio of anti-CD47 antibodies that have the potential to overcome multiple obstacles by which cancer evades the immune system.
The company maintains its research laboratories in St. Louis and a corporate office in Brisbane, CA.